PHARMACOLOGICAL PREVENTION OF VARICEAL BLEEDING - NEW DEVELOPMENTS

Citation
Jc. Garciapagan et J. Bosch, PHARMACOLOGICAL PREVENTION OF VARICEAL BLEEDING - NEW DEVELOPMENTS, Bailliere's clinical gastroenterology, 11(2), 1997, pp. 271-287
Citations number
84
Categorie Soggetti
Gastroenterology & Hepatology
ISSN journal
09503528
Volume
11
Issue
2
Year of publication
1997
Pages
271 - 287
Database
ISI
SICI code
0950-3528(1997)11:2<271:PPOVB->2.0.ZU;2-P
Abstract
The introduction of pharmacological therapy has been one of the major advances in the treatment of the complications of portal hypertension. Many drugs have been shown to reduce portal hypertension in patients with cirrhosis. However, the most widely used drugs and the only ones for which there is sufficient evidence, are the beta-blockers. These d rugs have been, up to now, the only accepted prophylactic therapy for oesophageal variceal bleeding and are also an alternative treatment to sclerotherapy or surgery to prevent variceal rebleeding. A reduction in portal pressure gradient by beta-blockers below 12 mmHg or by more than 20% of baseline values is associated with almost a total protecti on from oesophageal bleeding. Such a marked response in portal pressur e is only achieved in some patients receiving propranolol. New pharmac ological approaches with a greater portal pressure reducing effect may improve the beneficial effect of drugs in preventing variceal bleedin g. The more promising approach is the combined administration of beta- blockers and isosorbide-5-mononitrate, which has been shown to potenti ate the reduction in portal pressure and to be highly effective in ini tial randomized clinical trials.